NICE does not recommend Janssen’s Waldenstrom’s macroglobulinaemia candidate
The National Institute of Health and Care Excellence (NICE) has published draft guidance that does not recommend Janssen’s Imbruvica (ibrutinib) for treating some people with Waldenstrom’s macroglobulinaemia – a rare type of slow growing non-Hodgkin’s lymphoma.
Click on this link for more information.
